trending Market Intelligence /marketintelligence/en/news-insights/trending/Uv9sy0JHikeIyBaMwxzQrA2 content esgSubNav
In This List

GW Pharmaceuticals submits EMA application for epilepsy disorder drug

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


GW Pharmaceuticals submits EMA application for epilepsy disorder drug

GW Pharmaceuticals plc submitted its marketing authorization application to the European Medicines Agency for Epidiolex as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Dravet syndrome is a severe infantile-onset epileptic syndrome resulting in moderate to severe intellectual and developmental disabilities, and Lennox-Gastaut syndrome is characterized by multiple types of seizures and intellectual disability.

GW Pharmaceuticals in October completed the submission of its rolling application to the U.S. Food and Drug Administration for the same indication.

The application for Epidiolex is supported by data from three phase 3 studies, each of which met their primary endpoint.